报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
---|---|---|---|---|---|---|---|---|
2024-09-30 | 18.53% | -0.09% | -2.29% | 142/160 | 22.89% | 迪哲医药 | 97.73% | 行业排名> |
2024-06-30 | 18.96% | 2.88% | 20.44% | 142/160 | 33.26% | 百利天恒 | 97.99% | 行业排名> |
2024-03-31 | 15.74% | 3.83% | -7.98% | 141/160 | 51.37% | 百利天恒 | 98.92% | 行业排名> |
2023-12-31 | 17.11% | 20.35% | -7.73% | 144/160 | 51.38% | 迈威生物 | 98.93% | 行业排名> |
2023-09-30 | 18.54% | 30.05% | 0.61% | 143/160 | 32.75% | 迈威生物 | 99.59% | 行业排名> |
2023-06-30 | 18.43% | 20.49% | 21.55% | 140/160 | 38.61% | 迈威生物 | 99.8% | 行业排名> |
2023-03-31 | 15.16% | 18.21% | 6.67% | 139/160 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
2022-12-31 | 14.22% | -14.41% | -0.3% | 148/160 | 53.57% | 迈威生物 | 99.75% | 行业排名> |
2022-09-30 | 14.26% | -17.21% | -6.79% | 138/160 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
2022-06-30 | 15.3% | -18.74% | 19.25% | 144/160 | 21.79% | 迈威生物 | 99.44% | 行业排名> |
2022-03-31 | 12.83% | 2% | -22.77% | 133/160 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
2021-12-31 | 16.61% | -32.46% | -3.56% | 146/160 | 55.07% | 首药控股 | 99.93% | 行业排名> |
2021-09-30 | 17.22% | 2% | -8.51% | 130/160 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
2021-06-30 | 18.82% | -21.3% | -23.45% | 137/160 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
2020-12-31 | 24.59% | 10.25% | 2.81% | 133/160 | -143.08% | 艾力斯 | 99.4% | 行业排名> |
2020-06-30 | 23.92% | 2% | 7.24% | 120/160 | 54.32% | 首药控股 | 99.94% | 行业排名> |
2019-12-31 | 22.3% | 7.41% | 7.41% | 131/160 | -1204.25% | 泽璟制药 | 99.96% | 行业排名> |
2018-12-31 | 20.77% | 7.9% | 7.9% | 129/160 | -205.91% | 微芯生物 | 95.14% | 行业排名> |
2017-12-31 | 19.24% | 2% | 2% | 119/160 | 52.58% | 多瑞医药 | 95.59% | 行业排名> |